“Ready for What?”: Timing and Speculation in Alzheimer’s Disease Drug Development

Science, Technology, and Human Values 47 (3):597-622 (2022)
  Copy   BIBTEX

Abstract

“Readiness cohorts” are an innovation in clinical trial design to tackle the scarcity of time and people in drug studies. This has emerged in response to the challenges of recruiting the “right” research participants at the “right time” in the context of precision medicine. In this paper, we consider how the achievement of “readiness” aligns temporalities, biologies, and market processes of pharmaceutical innovation: how the promise of “willing bodies” in research emerges in relation to intertwined economic and biological time imperatives. Drawing on long-term engagement with the field of Alzheimer’s disease prevention and interviews with researchers from academia and the pharmaceutical industry, we describe the discursive construction and practical arrangement of readiness. This paper contributes to understandings of temporal specificity, or “timing,” within prevention research and casts critical light on the way this specificity—the threshold for “trial readiness”—relates to an opaque and highly speculative drug development pipeline. Extending the study of biomedical potential, as that which holds promise but may not yet exist, we consider how absences operate in adaptive trials. By highlighting these absences, we outline an opportunity for socio-ethical research to intervene in the speculative gaps of drug development.

Other Versions

No versions found

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 100,676

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
Integrating research and development: the emergence of rational drug design in the pharmaceutical industry.Matthias Adam - 2005 - Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 36 (3):513-537.
Institutional mistrust in the organization of pharmaceutical clinical trials.Jill A. Fisher - 2008 - Medicine, Health Care and Philosophy 11 (4):403-413.

Analytics

Added to PP
2022-04-13

Downloads
18 (#1,106,970)

6 months
5 (#1,032,319)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

The Anticipatory Politics of Improving Childhood Survival for Sickle Cell Disease.Gina Jae - 2018 - Science, Technology, and Human Values 43 (6):1122-1141.
Dementia Entanglements in a Postgenomic Era.Margaret Lock - 2011 - Science, Technology, and Human Values 36 (5):685-703.

View all 6 references / Add more references